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Background: Clinical observations or animal studies implicate enteric glial cells in motility disorders, irritable bowel syndrome, inﬂammatory bowel disease,
gastrointestinal (GI) infections, postoperative ileus, and slow transit constipation. Mechanisms underlying glial responses to inﬂammation in human GI tract are
not understood. Our goal was to identify the “reactive human enteric glial cell (rhEGC) phenotype” induced by inﬂammation, and probe its functional relevance.
Methods: Human enteric glial cells in culture from 15 GI-surgical specimens were used to study gene expression, Ca2+, and purinergic signaling by
Ca2+/ﬂuo-4 imaging and mechanosensitivity. A nanostring panel of 107 genes was designed as a read out of inﬂammation, transcription, purinergic
signaling, vesicular transport protein, channel, antioxidant, and other pathways. A 24-hour treatment with lipopolysaccharide (200 mg/mL)
and interferon-g (10 mg/mL) was used to induce inﬂammation and study molecular signaling, ﬂow-dependent Ca2+ responses from 3 mL/min to
10 mL/min, adenosine triphosphate (ATP) release, and ATP responses.
Results: Treatment induced a “rhEGC phenotype” and caused up-regulation in messenger RNA transcripts of 58% of 107 genes analyzed. Regulated genes
included inﬂammatory genes (54%/IP10; IFN-g; CxCl2; CCL3; CCL2; C3; s100B; IL-1b; IL-2R; TNF-a; IL-4; IL-6; IL-8; IL-10; IL-12A; IL-17A; IL-22; and
IL-33), purine-genes (52%/AdoR2A; AdoR2B; P2RY1; P2RY2; P2RY6; P2RX3; P2RX7; AMPD3; ENTPD2; ENTPD3; and NADSYN1), channels (40%/Panx1;
CHRNA7; TRPV1; and TRPA1), vesicular transporters (SYT1, SYT2, SNAP25, and SYP), transcription factors (relA/relB, SOCS3, STAT3, GATA_3, and
FOXP3), growth factors (IGFBP5 and GMCSF), antioxidant genes (SOD2 and HMOX1), and enzymes (NOS2; TPH2; and CASP3) (P , 0.0001). Treatment
disrupted Ca2+ signaling, ATP, and mechanical/ﬂow-dependent Ca2+ responses in human enteric glial cells. ATP release increased 5-fold and s100B decreased 33%.
Conclusions: The “rhEGC phenotype” is identiﬁed by a complex cascade of pro-inﬂammatory pathways leading to alterations of important molecular
and functional signaling pathways (Ca2+, purinergic, and mechanosensory) that could disrupt GI motility. Inﬂammation induced a “purinergic switch”
from ATP to adenosine diphosphate/adenosine/uridine triphosphate signaling. Findings have implications for GI infection, inﬂammatory bowel disease,
postoperative ileus, motility, and GI disorders.
(Inﬂamm Bowel Dis 2016;22:1812–1834)
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“G lial cell excitability” is determined by changes in intracellularfree Ca2+ signals. Emerging evidence suggests that enteric
glial cell (EGC) Ca2+ signals modulate motility and transit.1–3 Puri-
nergic Ca2+ signaling is an important mechanism in glial cell phys-
iology. Clinical observations and animal studies implicate EGC in
enteric nervous system (ENS) and motility disorders associated with
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slow transit constipation, irritable bowel syndrome, inﬂammatory
bowel disease, postoperative ileus, (POI), gastrointestinal (GI) infec-
tions, and barrier-pathology.4–6
Several recent studies have provided new insights on our
understanding of the pro-inﬂammatory mechanisms linked to the
reactive human enteric glial cell (rhEGC) phenotype and its
relevance as a therapeutic target for GI disorders. The study by
Turco et al7 was the ﬁrst to show that enteroinvasive Escherichia
coli interact with human enteric glial cells (hEGC), and the bac-
terial toxin lipopolysaccharide (LPS) acts via toll-like receptors 4
(TLR4) to stimulate production of nitric oxide (NO) through
a RAGE/s100B/inducible nitric oxide synthase (iNOS)–depen-
dent signaling pathway. Furthermore, hEGC can discriminate
between beneﬁcial and harmful bacteria for TLR4 activation (i.
e., only enteroinvasive Escherichia coli can activate TLR4). The
second study by Esposito et al8 explored palmitoylethanolamide
as a potential drug target for ulcerative colitis. It was shown to act
by blocking inﬂammation in animals and humans by targeting the
TLR4/s100B–dependent activation of peroxisome proliferator-
activated receptors a in EGC to inhibit nuclear factor (NF)-kB–
dependent inﬂammation. A third study in animals implicates the
EGC in POI. POI, common in abdominal surgery, is associated with
a signiﬁcant risk of postoperative complications, and carries a heavy
economic burden.6 POI may involve interleukin (IL)-1 receptor
signaling in EGC, and manipulations that block IL-1 signaling are
protective against development of POI.9 Therefore, a drug that can
interfere with IL-1 signaling in glia is a potential therapeutic target.
An emerging concept is that intestinal inﬂammation
associated with IBD or intestinal infection induces a “rhEGC phe-
notype” that could alter neural and motor behavior of the gut.6
Knowledge about the rhEGC phenotype remains limited, and its
functional consequences in glial networks are not known. To date,
no systematic analysis of the impact of inﬂammation or infection
has been done to identify the molecular and functional consequen-
ces in hEGC. To do this, and address this gap in knowledge, we
designed a custom panel of 107 genes based on their association
with intestinal inﬂammation and IBD to use as a readout for
changes in gene expression proﬁles in response to bacterial
LPS, in a model of hEGC cultures obtained from human surgical
specimens. We anticipated that the molecular readout would
reveal a signiﬁcant component of the molecular signature proﬁle
of the rhEGC phenotype. Furthermore, we hypothesized that sig-
niﬁcant disruption of glial function and Ca2+ signaling would
occur in response to bacterial lipopolysaccharide.
The hEGC culture model was shown to be a suitable model
to study glial function.10,11 Our recent study established that
hEGC displays Ca2+ oscillations, Ca2+ waves, and dynamic
changes in intracellular free Ca2+ levels in response to stimula-
tion. Propagating Ca2+ waves within the glial network also occur
in intact human ENS in situ.6 Furthermore, it was shown that
mechanical stimulation (MS) and purinergic signaling play key
roles in the physiology of hEGC–they trigger Ca2+ oscillations
and Ca2+ waves in hEGC. Multiple purinergic receptors and
mechanisms operate in hEGC, including adenosine receptors,
nucleotide ionotropic P2X channel receptors, and metabotropic
P2Y receptors.10–12 Purinergic signaling pathways are sensitive
to inﬂammation and changes in purinergic gene expression is
known to occur for receptors and enzymes in purinergic pathways
in response to gut inﬂammation.13 Therefore, molecular pathways
for purine genes were a major component of our gene platform, as
well as functional studies on purinergic and mechanosensory sig-
naling. We tested the hypothesis that inﬂammation would cause
signiﬁcant alterations in these signaling pathways. Functional end
points on the impact of inﬂammation on hEGC were Ca2+ signal-
ing and handling, purinergic (adenosine triphosphate [ATP]) Ca2+
responses, ATP release, and mechanosensitivity; these responses
are well characterized in cultures of hEGC.11
Our ﬁndings provided signiﬁcant new insights into the
molecular mechanisms and pathophysiology of the rhEGC pheno-
type. Inﬂammation has a profound inﬂuence on Ca2+ signaling,
purinergic signaling, and mechanosensitivity in hEGC. Overall,
bacterial LPS induction disrupts glial function and speciﬁcally, it
alters mechanical-evoked/ﬂow-dependent Ca2+ oscillations, ATP
responses, release of ATP and s100b, and Ca2+ handling. Disrup-
tion of glial function is likely to disrupt ENS and motility. The 65
genes shown to be sensitive to transcriptional regulation by LPS
induction represent new targets of investigation in GI infections,
neurological and GI disorders, POI, and inﬂammatory diseases, and
may lead to potential novel therapeutic strategies. Our study also
identiﬁed multiple candidate gene targets for purinergic pipeline
drugs. Pipeline purinergic drugs have shown efﬁcacy in preclinical
models of IBD, irritable bowel syndrome, and pain, and many are
in clinical trials for chronic inﬂammatory diseases (rheumatoid
arthritis/psoriasis/IBD), visceral pain, GI disorders, and Crohn’s
disease (CD) with some encouraging results.13
MATERIALS AND METHODS
Human Surgical Specimens
The institutional review board protocol is approved by the
ethics committee of the College of Medicine, The Ohio State
University. Informed consent was obtained to procure human
surgical tissue from colon or small bowel from patients with
polyps undergoing a colectomy (sigmoid colon) or patients
undergoing Roux-en-Y bypass surgery (jejunum). Human EGCs
in culture from 15 GI-surgical specimens were used to study gene
expression, Ca2+ and purinergic signaling by Ca2+/ﬂuo-4 imaging,
ATP release, and mechanosensitivity.
Human EGC Isolation from Human Surgical
Specimens and Culture
Tissue collection was performed by the surgeon and
immersed immediately in ice cold oxygenated Krebs solution
and promptly transported to the research facilities within 15
minutes in coordination with the clinical pathology team. For
isolating myenteric ganglia, tissue was pinned luminal side facing
up under a stereoscopic microscope and the mucosa, submucosa,
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and most of the circular muscle were dissected away using
scissors, and then ﬂipped over to remove longitudinal muscle by
dissection. For isolating submucous ganglia, the muscle layers are
ﬁrst removed by dissection, the tissue is ﬂipped over and mucosa
layer is carefully dissected away from the submucous plexus.
Myenteric or submucous plexus tissue was cut and enzymatically
dissociated as described elsewhere7 with modiﬁcations as follows:
Tissue (0.3–0.5 cm2 pieces) was dissociated in a mixture of pro-
tease/collagenase (1 mg/mL each in Hanks balanced salt solution)
for 60 minutes at 378C; Ganglia were removed from the enzy-
matic solution by spinning down (twice), and re-suspended in
Hanks balanced salt solution (once) and a mixture of Dulbecco’s
modiﬁed Eagle’s medium (DMEM)-F12, bovine serum albumin
0.1%, and DNase 50 mg/mL (once). Afterwards, ganglia in Hanks
balanced salt solution/DMEM-F12 were transferred into
a 100-mm culture dish and collected with a micropipette while
visualized under a stereoscopic microscope and plated into wells
of a 24-well culture plate and kept in DMEM-F12 (1:1) medium
containing 10% fetal bovine serum (FBS) and a mixture of anti-
biotics (penicillin 100 U/mL, streptomycin 100 mg/mL, and am-
photericin B 0.25 mg/mL) at 378C in an atmosphere of 5% CO2
and 95% humidity. After cells reach semiconﬂuence in 3 to 4
weeks (P1), hEGC were enriched and puriﬁed by eliminating/
separating ﬁbroblasts, smooth muscle, and other cells. EGC
enrichment and puriﬁcation was achieved by labeling the isolated
cells with magnetic micro beads linked to antispeciﬁc antigen,
D7-Fib, and passing them through a magnetic bead separation col-
umn following the manufacturer instructions (Miltenyi Biotec Inc.,
San Diego, CA). This puriﬁcation protocol was performed twice (P2
and P3) to reach cell enrichment of up to 10,000-fold, and 20,000
cells were plated on glass coverslips precoated with laminin/P-D-Lys
20 mg/mL in 50-mm bottom glass #0 culture dishes for ﬂuo-4/AM
calcium imaging. Cultured hEGC were kept until conﬂuent, and
harvested for additional experiments (4–10 d). The day of the exper-
iment, hEGC were stimulated as indicated. Parallel to this, cells at
each passage were split and seeded on plastic 25-mm2 culture ﬂasks
and used for study in passages 3 to passage 7.
Ca2+ Imaging
Feeding medium was removed and cells were incubated for
30 minutes at 378C with 2 mM ﬂuo-4/AM (Molecular Probes,
Eugene, OR) in DMEM with no FBS. After removing this solu-
tion, it was replaced with DMEM without FBS, and incubated at
378C for an additional 30 minutes. At the end of this incubation,
cells were removed from the incubator and placed on the stage of
an upright Nikon Eclipse FN1 microscope (Nikon, Tokyo, Japan)
with a ·20-water immersion objective. Calcium changes were
visualized with a high sensitivity and resolution ANDOR iXon
Ultra 897 EMCCD camera (Andor, Belfast, United Kingdom)
capable of 54 frames/s video recording. Cells were perfused with
a peristaltic pump at 4 mL/min with oxygenated Krebs solution
(mM: NaCl 120, KCl 6.0, MgCl2 1.2, NaH2PO4 1.35, NaHCO3
14.4, CaCl2 2.5, and glucose 12.7). A “solution inline heater”
(Warner Instruments, Inc., Hamden, CT) was used to maintain
the perfusion temperature at 36.58C6 0.58C. Time-series analysis
of [Ca2+]i was done at 0.1 to 0.034-second intervals (10–29
frames/s). Calcium image analysis was performed with NIS Ele-
ments Advanced Research software (Nikon).
Custom-design of Nanostring Panel of
107 Genes
Table 1 is a list of the 107 genes included in our custom-
designed panel of genes for nanostring analysis to identify
a rhEGC phenotype. The panel includes important genes in IBDs
(from animal and human studies).6,13–17
A nanostring panel of 107 genes was designed as a read out
of inﬂammation (of 23 cytokines and chemokines), 7 transcription
factors, 18 purinergic receptors (including adenosine, P2X and
P2Y–families), 12 purinergic enzymes (for adenosine, nucleotide,
and di-nucleotide metabolism), 6 vesicular transport proteins, 6
different cation channels (i.e., for K+, Ca2+, hemichannels, transient
receptor potential, and nicotinic channel), other enzymes, and post-
receptor signaling pathways (i.e., cAMP pathway, PKC pathway,
superoxide dismutase 2 [SOD2], caspase3/apoptotic pathway, heme
oxygenase pathway, nitric oxide synthase 2 [NOS2], other recep-
tors and proteins [including tight-junction proteins, growth factors,
glial proteins, retinol binding protein, cadherins, etc.]).
LPS Induction in hEGC
EGCs were grown in 12-well dishes (2 · 104 cells in each
well) in DMEM supplemented with 10% FBS and 1% penicillin–
streptomycin, until conﬂuence was reached (7–10 d). Cell cultures
were grown individually from 6 different patients and were used
at passages 4 to 7 for molecular signaling, Ca2+ imaging and
release studies. EGCs isolation was performed from jejunum
myenteric plexus (MP) (2 patients), colon MP (3 patients), and
colon submucous plexus (SMP) (1 patient).
To study the response of hEGCs to inﬂammatory mediators,
cells were incubated 24 hours with LPS (from Escherichia coli,
200 mg/mL, Sigma-Aldrich, St. Louis, MO) and interferon-gamma
(IFN-g) 10 mg/mL, Fisher Scientiﬁc (Item #285 IF 100, RHIFN-G
human IFN-g) in 400 mL of DMEM with 10% FBS and 1%
penicillin–streptomycin. For controls, the medium alone was used.
Supernatants (300 mL) were collected and immediately frozen in
liquid nitrogen for measurement of ATP or s100b release.
RNA Isolation
Cells were lysed in TRIZOL (Thermo Fisher Scientiﬁc,
Waltham, MA) and frozen at 2808C. Total RNA isolation was
performed using the TRIZOL method and after the separation of
the aqueous and organic phases, a RNA cleanup and concentra-
tion kit (NORGEN Biotek Corp., Ontario, Canada) was used to
purify and increase the concentration of the RNA. Gene expres-
sion analysis was conducted using the Nanostring nCounter Anal-
ysis System (Nanostring Technologies, Seattle, WA).
NanoString nCounter Gene Expression Assay
The RNA quality has been evaluated using Agilent RNA
6000 Nano Chip. NanoString nCounter technology is based on
Liñán-Rico et al Inﬂamm Bowel Dis  Volume 22, Number 8, August 2016
1814 | www.ibdjournal.org
Downloaded from https://academic.oup.com/ibdjournal/article-abstract/22/8/1812/4561984
by FACOLTA' DI LETTERE E FILOSOFIA user
on 09 March 2018
TABLE 1. Gene Set for Nanostring Analysis in hEGC
No. Symbol Ofﬁcial Full Name
Source http://www.genenames.org/
data/hgnc_data.php?hgnc_id¼262
Inﬂammation
1 CCL2 Chemokine (C-C motif) ligand 2 HGNC:10618
2 CCL3 Chemokine (C-C motif) ligand 3 HGNC:10627
3 IP10 Chemokine (C-X-C motif) ligand 10 HGNC:10637
4 Cxcl2 Chemokine (C-X-C motif) ligand 2 HGNC:4603
5 C3 Complement component 3 HGNC:1318
6 IFN-G IFN-gamma HGNC:5438
7 IL-1ra Interleukin-1 receptor antagonist HGNC:6000
8 IL-1b Interleukin-1, beta HGNC:5992
9 IL-10 Interleukin 10 HGNC:5962
10 IL-12 A Interleukin 12A HGNC:5969
11 IL-13 Interleukin 13 HGNC:5973
12 IL-17A Interleukin 17A HGNC:5981
13 IL-2R Interleukin 2 receptor, a HGNC:6008
14 IL-22 Interleukin 22 HGNC:14900
15 IL-23A Interleukin 23, alpha subunit p19 HGNC:15488
16 IL-33 Interleukin 33 HGNC:16028
17 IL-4 Interleukin 4 HGNC:6014
18 IL-5 Interleukin 5 HGNC:6016
19 IL-6 Interleukin 6 HGNC:6018
20 IL-8 Interleukin 8 HGNC:6025
21 PLAT Plasminogen activator, tissue HGNC:9051
22 PDGFRA Platelet-derived growth factor receptor, alpha polypeptide HGNC:8803
23 TNF-a Tumor necrosis factor HGNC:11892
Transcription factors
24 AHR Aryl hydrocarbon receptor HGNC:348
25 FOXP3 Forkhead box P3 HGNC:6106
26 GATA-3 GATA binding protein 3 HGNC:4172
27 STAT3 Signal transducer and activator of transcription 3 HGNC:11364
28 SOCS3 Suppressor of cytokine signaling 3 HGNC:19391
29 RELB V-rel avian Reticuloendotheliosis viral oncogene
homlog B
HGNC:9956
30 RELA V-rel avian reticuloendotheliosis viral oncogene homolog A HGNC:9955
Purinergic receptors
31 ADORA1 Adenosine A1 receptor HGNC:262
32 Adora2a Adenosine A2a receptor MGI:99402
33 Adora2b Adenosine A2b receptor MGI:99403
34 ADORA3 Adenosine A3 receptor HGNC:268
35 P2RX1 Purinergic receptor P2X, ligand-gated ion channel, 1 HGNC:8533
36 P2RX2 Purinergic receptor P2X, ligand-gated ion channel, 2 HGNC:15459
37 P2RX3 Purinergic receptor P2X, ligand-gated ion channel, 3 HGNC:8534
38 P2RX4 Purinergic receptor P2X, ligand-gated ion channel, 4 HGNC:8535
39 P2RX5 Purinergic receptor P2X, ligand-gated ion channel, 5 HGNC:8536
40 P2RX7 Purinergic receptor P2X, ligand-gated ion channel, 7 HGNC:8537
41 P2RY1 Purinergic receptor P2Y, G-protein coupled, 1 HGNC:8539
42 P2RY11 Purinergic receptor P2Y, G-protein coupled, 11 HGNC:8540
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TABLE 1 (Continued )
No. Symbol Ofﬁcial Full Name
Source http://www.genenames.org/
data/hgnc_data.php?hgnc_id¼262
43 P2RY12 Purinergic receptor P2Y, G-protein coupled, 12 HGNC:18124
44 P2RY13 Purinergic receptor P2Y, G-protein coupled, 13 HGNC:4537
45 P2RY14 Purinergic receptor P2Y, G-protein coupled, 14 HGNC:16442
46 P2RY2 Purinergic receptor P2Y, G-protein coupled, 2 HGNC:8541
47 P2RY4 Pyrimidinergic receptor P2Y, G-protein coupled, 4 HGNC:8542
48 P2RY6 Pyrimidinergic receptor P2Y, G-protein coupled, 6 HGNC:8543
Purinergic enzymes
49 NT5E 50-nucleotidase, ecto (CD73) HGNC:8021
50 ADA1 Adenosine deaminase HGNC:186
51 AMPD2 Adenosine monophosphate deaminase 2 HGNC:469
52 AMPD3 Adenosine monophosphate deaminase 3 HGNC:470
53 CECR1 Cat eye syndrome chromosome region, candidate 1 HGNC:1839
54 DDP4 Dipeptidyl-peptidase 4 HGNC:3009
55 ENTPD1 Ectonucleoside triphosphate diphosphohydrolase 1 HGNC:3363
56 ENTPD2 Ectonucleoside triphosphate diphosphohydrolase 2 HGNC:3364
57 ENTPD3 Ectonucleoside triphosphate diphosphohydrolase 3 HGNC:3365
58 NADSYN1 NAD synthetase 1 HGNC:29832
59 NMNAT1 Nicotinamide nucleotide adenylyltransferase 1 HGNC:17877
60 NMRK1 Nicotinamide riboside kinase 1 HGNC:26057
Vesicular transport proteins
61 SYP Synaptophysin HGNC:11506
62 SNAP25 Synaptosomal-associated protein, 25 kDa HGNC:11132
63 SYT1 Synaptotagmin I HGNC:11509
64 SYT2 Synaptotagmin II HGNC:11510
65 STX1A Syntaxin 1A (brain) HGNC:11433
66 USO1 USO1 vesicle docking protein homolog HGNC:30904
Cation channels
67 CACNA1B Ca2+ channel, voltage-dependent, N type, alpha 1B HGNC:1389
68 KCNE1 K+ voltage-gated channel, Isk- member 1 HGNC:6240
69 PANX1 Pannexin 1 HGNC:8599
70 TRPV1 Transient receptor potential cation channel, V1 HGNC:12716
71 TRPA1 Transient receptor potential cation channel, A, member 1 HGNC:497
72 CHRNA7 a7 nicotinic receptor HGNC:1960
Enzymes and signaling pathways
73 PRKACA cAMP-dependent PKA HGNC:9380
74 CASP3 Caspase 3, apoptosis-related cysteine peptidase HGNC:1504
75 HMOX1 Heme oxygenase (decycling) 1 HGNC:5013
76 NOS2 Nitric oxide synthase 2, inducible HGNC:7873
77 PDE4B Phosphodiesterase 4B, cAMP-speciﬁc HGNC:8781
78 PRKCe Protein kinase C, epsilon HGNC:9401
79 SOD2 Superoxide dismutase 2, mitochondrial HGNC:11180
80 TPH1 Tryptophan hydroxylase 1 HGNC:12008
81 TPH2 Tryptophan hydroxylase 2 HGNC:20692
Receptors and proteins
82 ADIPOR1 Adiponectin receptor 1 HGNC:24040
83 ADIPOR2 Adiponectin receptor 2 HGNC:24041
Liñán-Rico et al Inﬂamm Bowel Dis  Volume 22, Number 8, August 2016
1816 | www.ibdjournal.org
Downloaded from https://academic.oup.com/ibdjournal/article-abstract/22/8/1812/4561984
by FACOLTA' DI LETTERE E FILOSOFIA user
on 09 March 2018
direct detection of target molecules using color-coded molec-
ular barcodes, providing a digital simultaneous quantiﬁcation
of the number of target molecules. Total (RNA 100 ng) was
hybridized overnight with nCounter Reporter (20 mL) probes in
hybridization buffer and in excess of nCounter Capture probes
(5 mL) at 658C for 16220 hours. The hybridization mixture
containing target/probe complexes was allowed to bind to mag-
netic beads containing complementary sequences on the cap-
ture probe. After each target found a probe pair, excess probes
were washed, followed by a sequential binding to sequences on
the reporter probe. Biotinylated capture probe–bound samples
were immobilized and recovered on a streptavidin-coated car-
tridge. The abundance of speciﬁc target molecules was then
quantiﬁed using the nCounter digital analyzer. Individual ﬂuo-
rescent barcodes and target molecules present in each sample
were recorded with a CCD camera by performing a high-
density scan (600 ﬁelds of view). Images were processed inter-
nally into a digital format and were normalized using the Nano-
String nSolver Software analysis tool. Counts were normalized
for all target RNAs in all samples based on the positive control
RNA, to account for differences in hybridization efﬁciency
and posthybridization processing including puriﬁcation and
immobilization of complexes. The average was normalized
by background counts for each sample obtained from the aver-
age of the 8 negative control counts. Subsequently, a normali-
zation of mRNA content was performed based on internal
reference housekeeping genes Gusb, TBP, NMNAT1, RBP1,
STX1A, and CTNNB1 using nSolver Software (NanoString
Technologies).
LPS Induction and Detection of ATP Secretion
Using the Luciferin–luciferase Assay
Luciferin–luciferase assay was used to monitor basal secre-
tion of ATP according to the manufacturer’s instructions (ATP-lite,
Perkin Elmer, Waltham, MA) using 100 mL of the supernatant.
EGCs were grown in 12-well dishes (2 · 104 cells in each
well) in DMEM supplemented with 10% FBS and 1% penicillin–
streptomycin, until conﬂuence was reached (7–10 d). Cell cultures
were grown individually from 4 different surgical specimens and
were used at passages 4 to 7. EGCs isolation was performed from
MP of 3 surgical patients (2 jejunum, 1 colon) and SMP of
1 patient (colon). Preliminary analysis did not reveal any differ-
ences in amount of ATP secretion in each surgical specimen and
therefore, data in different surgical specimens were pooled
TABLE 1 (Continued )
No. Symbol Ofﬁcial Full Name
Source http://www.genenames.org/
data/hgnc_data.php?hgnc_id¼262
84 APOE Apolipoprotein E HGNC:613
85 AGTR1A Angiotensin II receptor, type 1 HGNC:336
86 AGTR2 Angiotensin II receptor, type 2 HGNC:338
87 CDH1 Cadherin 1, type 1, E-cadherin (epithelial) HGNC:1748
88 CTNNB1 Catenin (cadherin-associated protein), b 1 HGNC:2514
89 CLDN1 Claudin 1 HGNC:2032
90 CLDN3 Claudin 3 HGNC:2045
91 CLDN5 Claudin 5 HGNC:2047
92 GMCSF Colony stimulating factor 2 (granulocyte-macrophage) HGNC:2434
93 GFAP Glial ﬁbrillary acidic protein HGNC:4235
94 GUSB Glucuronidase, beta HGNC:4696
95 HP Haptoglobin HGNC:5141
96 HGF Hepatocyte growth factor HGNC:4893
97 IGFBP5 Insulin-like growth factor binding protein 5 HGNC:5474
98 OCLN Occludin HGNC:8104
99 PIGR Polymeric immunoglobulin receptor HGNC:8968
100 PSMC3 Proteasome 265 subunit, ATPase3 HGNC:9549
101 RBP1 Retinol binding protein 1, cellular HGNC:9919
102 S100B S100 calcium binding protein B HGNC:10500
103 TACR1 Tachykinin receptor 1 HGNC:11526
104 TBX21 Thromboxin 21 HGNC:11599
105 TGFB1 Transforming growth factor, beta 1 HGNC:11766
106 VSNL1 Visinin-like 1 HGNC:12722
107 VDR Vitamin D3 receptor HGNC:12679
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together. To study the effect of treatment on ATP secretion, cells
were incubated with LPS+IFN-g in 400 mL of DMEM with 10%
FBS and 1% penicillin–streptomycin. For controls, the medium
alone was used. Supernatants (300 mL) were collected and imme-
diately frozen in liquid nitrogen for measurement of ATP (ATP-
lite, Perkin Elmer).
LPS Induction and Detection of s100b
Protein Secretion
The secretion of s100b was detected in a100 mL superna-
tant sample using an enzyme-linked immunosorbent assay kit
(#RD192090100R, Biovendor LLC, Asheville, NC) according
to the manufacturer’s instructions. The secretion of s100b protein
was done in the same supernatant samples as those used for ATP
release (see above protocol).
Experimental Strategies (additional information is included
in Figs. 1–8)
1. LPS (LPS+IFN-g) induction was used as a way to induce
inﬂammation in hEGC and evaluate (1) molecular signaling
by nanostring analysis, (2) mechanosensitivity by monitor-
ing Ca2+ signals with ﬂuo-4/Ca2+ imaging, (3) Ca2+ han-
dling, (4) ATP Ca2+ responses, and (5) secretion of
mediators from hEGC.
2. LPS induction (LPS+IFN-g) was used to evaluate the
rhEGC phenotype, and identify the mRNA signature proﬁle
in response to inﬂammation for a custom panel of 107
genes listed in Table 1.
3. LPS induction (LPS+IFN-g) was used to evaluate the
impact of inﬂammation on secretion of the purinergic glio-
transmitter ATP and the glial protein s100b.
4. LPS induction (LPS+IFN-g) was used to evaluate the impact
of inﬂammation on mechanical-evoked Ca2+ responses in
response to increase in perfusion ﬂow from 2 mL/min to
10 mL/min. We found in preliminary experiments that
increase in ﬂow induces Ca2+ oscillations in hEGC in cul-
ture.11 Therefore, we tested the effect of LPS induction on
ﬂow-dependent Ca2+ oscillations. Cells responded in 3 dif-
ferent ways to increase in ﬂow: (1) in cells with no oscilla-
tions (quiescent/ﬂat line) at 2 mL/min (low ﬂow), increase in
ﬂow to 10 mL/min could elicit oscillations, (2) in cells with
Ca2+ oscillations at 2 mL/min (low ﬂow), an increase in ﬂow
to 10 mL/min did not cause any further response, and (3) in
cells with low ﬂow oscillations, increase in ﬂow caused
a change in the pattern of oscillations.
5. LPS induction was used to evaluate the effect of inﬂammation
on exogenous ATP-induced Ca2+ responses to 100 mM ATP
perfusion for 1 to 2 minutes. Peak Ca2+ responses and occur-
rence of Ca2+ transients were analyzed in response to LPS.
6. LPS induction was used to evaluate the effect of inﬂamma-
tion on store-operated Ca2+ entry (SOCE) into hEGC. The
protocol used involved inducing Ca2+ oscillations by
increasing the ﬂow rate, and then blocking Ca2+ oscillations
by perfusing 0.0Ca2+ buffer (+200 mM ethylene glycol-bis
(b-aminoethyl ether)-N,N,N1,N1-tetraacetic acid (EGTA))
to block Ca2+ entry. Re-introduction of Ca2+ to the Krebs
buffer (2 mM CaCl2) elicits a robust Ca2+ response by
stimulating Ca2+ entry through SOCE channels that are
activated by Ca2+ depletion. The magnitude or occurrence
of the SOCE response was measured and compared
between LPS treatment and control. Note: ATP Ca2+ re-
sponses occur in the absence of extracellular Ca2+, and
inﬂuence of LPS on ATP responses was tested in this pro-
tocol as well (in some experiments).
Cell Viability Assay
Cell viability was tested in cell cultures using the Nuclear-
ID Blue-green cell viability reagent (ENZO, Farmingdale, NY)
following the protocol for adherent cells.
Immunocytochemistry
To conﬁrm the identity of glial cells in our hEGC cultures,
immunoﬂuorescent labeling was done for glial markers (s100b,
glial ﬁbrillary acidic protein GFAP), smooth muscle/epithelial
actin, or ﬁbroblasts. hEGCs were ﬁxed in 4% paraformaldehyde
for 15 minutes at room temperature, rinsed 3 times with cold
phosphate-buffered saline (PBS) 0.1 M and placed at 48C until
further processing. Cells were treated with 0.5% Triton X, 10%
normal donkey serum in PBS to permeabilize the cells and block
nonspeciﬁc antibody binding for 30 minutes at room temperature.
Primary antibodies were diluted in PBS-0.1% Triton X, and 2%
normal donkey serum, and were incubated with cells overnight
(18–24 h) at 48C. Next day preparations were rinsed 3 times in
0.1M PBS/1 minute and incubated 60 minutes at room tempera-
ture in secondary antibodies diluted in PBS-0.1%, Triton X, and
2% normal donkey serum. Monoclonal mouse anti-S100b anti-
body (1:100–1:500 dil., cat #ab11178; Abcam, Cambridge, MA),
mouse monoclonal anti-a smooth muscle/epithelial actin antibody
(1:50–1:500 dil., cat #ab18147; Abcam), rabbit anti-GFAP anti-
body (1:500 dil., cat #z0334; DAKO, Carpinteria, CA), and
monoclonal mouse antiﬁbroblast/epithelial cell antibody (1:100–
1:500 dil., cat #NB600–777; Novus Biologicals, Littleton, CO)
were used for analysis. Alexa Fluor 488 or 568 donkey anti-
mouse or anti-rabbit secondary antibodies were used at a dilution
of 1:400 (Cambridge, MA). Omission of primary antibodies was
used to test for background staining of the secondary antibodies.
Preabsorption of primary antisera with immunogenic peptides
abolished immunoreactivity. Data conﬁrmed previous reports by
Turco et al,7 and is not shown, except for illustrating that cells
express s100b immunoreactivity.
Statistics
Nanostring data was normalized in nSolver 2.5 according to
manufacturer recommendations. Two-tailed Student’s t tests were
used to test for signiﬁcant difference in gene expression between
control and LPS. Box plots were created to depict differential
gene expression between control and LPS tissue on their original
scale. Data is reported as a fold change in gene expression,
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FIGURE 1. Gene expression changes in hEGC induced by bacterial LPS+IFN-g stimulation. A, Heat map of the normalized mRNA counts of un-
stimulated (control) and stimulated (LPS+IFN-g) hEGC of each sample. The colors of the heat map refer to expression level with respect to the
mean for a gene across all the samples (green is lower than the mean and red is above). Data is Z-score transformed for each gene. Dendrograms
(clusters) are shown for sample clustering (top of ﬁgure) and for gene clustering (left side of ﬁgure). Human EGC were plated at 20,000 cells/dish
and grown to a conﬂuent culture. Cells were incubated with LPS+IFN-g for 24 hours. Gene expression levels in hEGC were determined for
a custom panel of 107 genes using Nanostring probe-based analysis of 100 ng of total RNA in multiple samples from each of 4 patients. B, s100B
immunoreactivity in hEGC (40,60-diamidino-2-phenylindole [DAPI] nuclear counter-stain, blue).
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mRNA counts/100 ng total RNA sample, or log2 mRNA counts
for each of 107 genes analyzed by nanostring. Differences
between control and treatment groups are signiﬁcant at P ,
0.01 to take into consideration that ;100 different genes were
being analyzed (Most changes observed in our study were signif-
icant at a P , 0.0001).
Chi-square analysis was used to analyze data for effects of
treatment (LPS+IFN-g) on Ca2+ oscillations, MS, ATP responses,
and SOCE responses (i.e., restore normal 2 mM Ca2+ in the Krebs
buffer solution). A 2-tailed Student’s t test was used to evaluate
differences between control and treatment for ATP release and
s100b protein release from hEGC.
FIGURE 2. Gene expression changes in inﬂammatory genes induced by bacterial LPS+IFN-g stimulation in hEGC. A, Fold change in normalized
gene expression for chemokine and cytokine genes. Discoveries (*) were determined by false discovery rate following multiple t test analysis;
*signiﬁcant fold increase in mRNA expression in response to treatment, at P , 0.0001. B, Box plots of mRNA counts/100 ng sample showing
differences in gene expression between control (CON, unstimulated) and LPS (stimulated) samples of hEGC (n ¼ 12–16 samples of hEGC obtained
from GI surgical specimens of 4 human subjects).
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Heat Map Analysis
A heat map was generated in nSolver from normalized data
of individual samples in control or treatment group (LPS+IFN-g).
The colors of the heat map refer to expression level with respect to
the mean for a gene across all the samples (green is lower than the
mean and red is above). By default, the data is Z score trans-
formed for each gene so that all of the means and standard
deviations of all of the genes line up. Thus a 2-fold increase in
expression will look the same for a gene expressed at hundreds of
counts versus one expressed in the hundreds of thousands. Den-
drograms (clusters) were created for genes and samples in nSolver
using agglomerative clustering. Eucledian distance was used to
look for similarities between clusters. Centroid methodology was
used to link clusters together. The linkage method (how values are
FIGURE 3. Gene expression changes induced by bacterial LPS+IFN-g stimulation in hEGC for (A) transcription factors, (B) vesicular transport
proteins, (C) cation channels, (D) enzymes and signaling pathways, (E) receptors and proteins. Data represent fold changes in normalized gene
expression. Discoveries (*) were determined by false discovery rate following multiple t test analysis; *signiﬁcant fold increase in mRNA expression
in response to treatment, at P , 0.0001 (n ¼ 12–16 samples of hEGC obtained from GI surgical specimens of 4 human subjects). The box-plots of
mRNA counts/100 ng sample showing differences in gene expression in response to treatment are included in Figs. 1 and 2, Supplemental Digital
Content 1, http://links.lww.com/IBD/B301.
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assigned to a branch containing multiple genes) used centroid
methodology.
Interactions Between Purines and
Inﬂammatory Genes
General linear models were ﬁt with main effects for purine
group and inﬂammatory markers, and we tested whether there was
an interaction between the 2 variables, by evaluating whether the
effect of each inﬂammatory gene on purine gene was signiﬁcantly
different by study group. Separate models were ﬁt for each
outcome (purine gene) and predictor (inﬂammatory gene) com-
bination. Signiﬁcance was adjusted by controlling the mean
number of false positives. Signiﬁcance was accepted at P ¼
0.01 to correct for multiple comparisons. Statistical software
SAS 9.3 and R was used for analysis.
RESULTS
Data is summarized in Figures 1–9, Figs. 1 and 2, Sup-
plemental Digital Content 1, http://links.lww.com/IBD/B301,
FIGURE 4. The gene expression proﬁle of 29 purine genes involved in purinergic signaling pathways, including adenosine receptors, P2X-receptors,
P2Y receptors, and enzymes involved in metabolic degradation of purine nucleotides, and di-nucleotides. A, Box-plots of gene expression for mRNA
counts/100 ng sample. DDP4 and NT5E have the highest expression in hEGC. B, Box-plots of gene expression displayed on a log2 scale for mRNA
counts better revealed differences in mRNA expression of control (unstimulated) hEGC.
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Tables 1 and 2, and Tables 1–3, Supplemental Digital Content 2,
http://links.lww.com/IBD/B302. Nanostring analysis was used
to evaluate the impact of inﬂammation (LPS+IFN-g) on gene
expression in hEGC. The code set included a custom-designed
set of 107 genes associated with IBDs (Table 1) representing
mRNA gene expression for inﬂammatory genes, purinergic sig-
naling genes, vesicular release proteins, neurotransmitters, sen-
sory signaling genes, transcription factors, postreceptor
signaling enzymes, and genes linked to free radical pathways.
A heat map showing the molecular signature of the “rhEGC
phenotype” is shown in Figure 1A. Cells are immunoreactive
for the glial Ca2+ binding protein s100b (Fig. 1B).
LPS induced a “rhEGC phenotype” and caused upregu-
lation in mRNA transcripts of 58% of 107 genes including
subsets of inﬂammatory genes (54%), purine genes (52%),
channels (40%), vesicular transport, transcription factors, free
radical/other pathway genes; 95% of these mRNAs were up-
regulated by LPS treatment; only 3 mRNAs were down-
regulated by treatment.
LPS Induction of Inﬂammatory Pathways
LPS induction caused mRNA up-regulation in inﬂamma-
tory genes. These included 7 chemokines (IP10, IFN-g, CxCl2,
CCl3, CCl2, C3, and s100B), 12 cytokines (IL-1b, IL-2R, tumor
necrosis factor [TNF]-a, IL-4, IL-6, IL-8, IL-10, IL-12A, IL-17A,
IL-22, IL-23A, and IL-33), and 2 growth factors (IGFBP5 and
GMCSF). Fold changes (;ranging from 3-fold to 1900-fold
increase in mRNA expression) for inﬂammatory genes are sum-
marized in Figure 2 and Table 1, Supplemental Digital Content 2,
http://links.lww.com/IBD/B302.
LPS Induction of Transcription Factors
Several transcription factors were up-regulated by LPS
induction (Fig. 3A). RELB and RELA, transcription factors involved
in NFkB induction were up-regulated by 14-fold and 5-fold, respec-
tively. Other transcription factors including suppressor of cytokine
signaling 3 (SOCS3), forkhead box P3 (FOXP3), GATA_3, signal
transducer and activator of transcription 3 (STAT3), and aryl hydro-
carbon receptor were also up-regulated several fold (2–5-fold).
FIGURE 5. Gene expression changes in purine genes induced by bacterial LPS+IFN-g stimulation in hEGC. A, Fold changes in normalized gene
expression for purinergic receptor genes. B, Fold changes in gene expression for purinergic enzymes involved in metabolic degradation of purines.
Discoveries (*) were determined by false discovery rate following multiple t test analysis; *signiﬁcant fold increase in mRNA expression in response
to treatment, at P , 0.0001. C, Box plots of mRNA counts/100 ng sample showing differences in gene expression between control (CON,
unstimulated) and LPS (stimulated) samples of hEGC (n ¼ 12–16 samples of hEGC obtained from GI surgical specimens of 4 human subjects).
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Vesicular Transport Proteins
Gene mRNA expression of vesicular transport proteins
were up-regulated by LPS induction. SYT2 was upregulated by 6-
fold, followed by SNAP25 (+4-fold) and SYP (+4-fold). SYT1,
US01, and STX1A were not affected by treatment (Fig. 3B).
Cationic Channels
There was a 15-fold up-regulation of the sensory TRPA1
channel (transient receptor potential A1) in hEGC. In contrast, the
TRPV1 channel (transient receptor potential V1) was only
marginally up-regulated by treatment (+1.72-fold). The hemi-
channel pannexin 1 (Panx1) and the a7-nicotinic cholinergic
channel (CHRNA7) were up-regulated ; 3-fold by treatment.
Expression of other channels (CACNA1B/N-type Ca2+ channel,
KCNE1/K+ channel or TACR1/tachykinin receptor/not shown)
remained the same (Fig. 3C).
Enzymes, Signaling, and Free
Radical Pathways
Free radical pathway enzymes were highly up-regulated in
hEGC in response to LPS induction. These included SOD2
(increase 45-fold), NOS2 (+6-fold), TXB21 (+18-fold), and heme
oxygenase-1 (HMOX1) (+2-fold). Caspase 3, an enzyme involved
in apoptosis was up-regulated marginally by 1.78-fold.
The expression of a number of other signaling pathway
enzymes and proteins were affected by LPS induction. The
calcium binding protein s100b was up-regulated by 3-fold, but the
expression of GFAP remained the same. PRKCe was not altered.
CDH1 (E-cadherin) was up-regulated by 3-fold. The cAMP-
dependent protein kinase-A enzyme PRKACA was the only
enzyme that was down-regulated by LPS induction (P ,
0.0001). The cyclic adenosine 30,50-monophosphate (cAMP)-
dependent phosphodiesterase (PDE) 4B enzyme was up-regulated
by 3-fold in response to LPS. The expression of mRNA for en-
zymes involved in the metabolism of serotonin was selectively
up-regulated by LPS induction. The mRNA transcripts for tryp-
tophan hydroxylase (TPH) 2 enzyme for the metabolism of sero-
tonin was up-regulated by 5-fold, whereas the expression of the
TPH1 enzyme, known to be highly expressed in enterochromafﬁn
cells remained the same (see Supplemental Table 3, Supplemental
Digital Content 2, http://links.lww.com/IBD/B302).
Expression of Other Receptors and Proteins
Expression of angiotensin receptors AT1A (AGTRIA) and
AT2A (AGTR2) were up-regulated 9-fold and 7-fold, respec-
tively. The vitamin D3 receptor was up-regulated 2-fold. The
mRNA expression for several barrier (tight-junction) proteins
was increased by LPS induction. Claudin (CLDN)1 mRNA
expression was increased by 29-fold and CDH1 by 3-fold; mRNA
expression of CLDN3, CLDN5, and VSNL1 was not signiﬁcantly
altered by LPS (see Supplemental Table 3, Supplemental Digital
Content 2, http://links.lww.com/IBD/B302).
Expression and Detection of mRNA
Transcripts for Purinergic Genes in hEGC
Differential and relative expression of mRNAs for various
purine genes in hEGCs suggests that a complex array of potential
purinergic signaling mechanisms operate in hEGCs (Fig. 4A, B).
The mRNA expression proﬁle for purinergic signaling genes was
revealed by nanostring analysis of 29 purine genes including P1,
P2X, P2Y receptors and enzymes involved in metabolic pathways
for endogenous purines (ATP, uridine triphosphate [UTP], aden-
osine diphosphate [ADP], adenosine [ADO], b-nicotinamide ade-
nine dinucleotide [NAD]). The mRNA counts for 100 ng of total
RNA/sample indicate that NT5E (CD73) has the highest expres-
sion of all purine genes, followed by dipeptidyl-peptidase
4 (DDP4), adenosine monophosphate deaminase (AMPD) 3,
P2XR5, and adenosine deaminase (ADA) 2. All 29 purine genes
were expressed in hEGCs (Fig. 4A, B).
LPS Induction of Purinergic
Signaling Pathways
Data for purine genes with signiﬁcant up-regulation in
response to LPS induction are summarized in Figure 5A for pu-
rinergic receptors and Figure 5B for purinergic enzymes. Table 2,
Supplemental Digital Content 2, http://links.lww.com/IBD/B302
includes the fold-changes in mRNA expression for purine genes.
LPS induction did not have any effect on the mRNA
expression in 12 of 29 purine genes (41.3%) including ADOA3,
ENTPD1, P2RX2, DDP4, P2RX4, P2RY12, ADORA1, ADA1,
P2RX1, P2RY4, CECR1 (ADA2). LPS induction causes
FIGURE 6. Basal release of mediators was altered in hEGC treated for
24 hours with bacterial LPS and IFN-g. A, Treatment increased basal
release (unstimulated) of the purinergic gliotransmitter ATP from
hEGC (P ¼ 0.0017). B, In contrast, the same treatment with LPS and
IFN-g caused a signiﬁcant reduction in s100b release (P ¼ 0.003). Data
is presented as mean 6 SEM for 13 to 14 samples for each condition.
Data represents pooled culture results from hEGC obtained from
surgical specimens of 4 human subjects.
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FIGURE 7. Ca2+ responses and ﬂow-dependent Ca2+ responses in hEGC are disrupted by bacterial LPS treatment. (A–G) Control cell Ca2+ re-
sponses. A, A typical example of a control hEGC that responds to increasing pulsatile ﬂow of the peristaltic pump from 1.6 mL/min to 10 mL/min.
Flow induces rhythmic Ca2+ oscillations. Change in ﬂow is used as a physiologic mechanical stimulus (MS) to trigger Ca2+ oscillations. The cell does
not have oscillations at low ﬂow. B, Another cell depicting oscillations at low ﬂow. Increasing ﬂow changes the pattern of the oscillations, and the
response is entirely dependent on extracellular Ca2+ levels since 0.0 Ca2+ + ethylene glycol-bis(b-aminoethyl ether)-N,N,N1,N1-tetraacetic acid
(EGTA) buffer abolishes the response. C, Example of a cell that displays rhythmic Ca2+ oscillations at low ﬂow and does not change its response
with increase in ﬂow. The oscillations depend on extracellular Ca2+levels. D, Example of a cell with a single Ca2+ transient at low ﬂow and a high
frequency Ca2+ oscillation at high ﬂow. E, A cell displaying distinct Ca2+ responses at low and high ﬂow. F, Example of another cell responding to
change in ﬂow. Rarely, Ca2+ spikes can occur in 0.0 Ca2+ + EGTA (#10% of hEGC). The ATP-induced Ca2+ response does not depend on
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signiﬁcant mRNA up-regulation in 17 of 29 purine genes
(59.7%). Up-regulation occurred in Adora2a (27-fold), AMPD3
(8-fold), P2RY13 (6-fold), P2RY2 (4-fold), P2RX3 (4-fold),
P2RX7 (3.8-fold), P2RY1 (3-fold), Panx1 (3-fold), P2RY14
(2.9-fold), ENTPD3 (2.9-fold), ENTPD2 (2.8-fold), P2RY6
(2.5-fold), NADSYN1 (2.1-fold), NT5E (1.7-fold), NMRK1
(1.3-fold), P2Y11 (1.3-fold), and Adora2b (1.7-fold). None of
the purine genes showed any down-regulation.
Signiﬁcant Interactions Between Purine
Genes and Inﬂammatory Genes
Analysis of the change in slope of the linear relationship
between mRNA expression in purine genes versus inﬂammatory
genes between control and LPS-treated hEGC was used to
determine signiﬁcant interactions. Data is summarized in Table 2
for signiﬁcant interactions. The data suggests that purine gene
expression/dysregulation is related to the expression of speciﬁc
inﬂammatory genes. Overall, in 9 of 17 purine genes that mRNA
expression was up-regulated by LPS induction, there was a signif-
icant change in the slope of the linear relationship. For Adora2a,
AMPD3, CD73, ENTPD2, and ENTPD3 there was an increase in
slope for some genes and a decrease in slope for others. In con-
trast, for P2RX3, P2RX7, P2RY6, and P2RY1, there was
a decrease in slope of the relationship. Therefore, a positive or
negative interaction is revealed between purines and inﬂammatory
genes depending on the speciﬁc purine gene. An additional anal-
ysis was done between Panx1, inﬂammatory, and purine genes.
LPS induction decreased the slope of the linear relationship
between mRNA expression of Panx1 and Caspase 3 or P2RX5.
Release of Mediators from hEGC Is Altered by
LPS Treatment
Basal release of mediators was altered in hEGC treated for
24 hours with bacterial LPS and IFN-g. Treatment increased basal
release of the purinergic gliotransmitter ATP from hEGC (P ¼
0.0017) (Fig. 6A). In contrast, the same treatment with LPS and
IFN-g caused a signiﬁcant reduction in s100b release (P ¼ 0.003)
(Fig. 6B).
LPS Alters Ca2+ Signaling, ATP-responses,
Mechanosensitivity, and SOCE Responses
There was a clear and discrete change in ﬂow-dependent
mechanosensitivity. The ﬂow-dependent (MS) activation of Ca2+
oscillations is dramatically reduced in hEGC treated with LPS,
whereas cells are more likely to respond with Ca2+ oscillations
under baseline/low ﬂow stimulation. The proportion of cells
responding to high ﬂow was reduced by LPS treatment (Figs. 7
and 8).
Increase in the ﬂow induces rhythmic Ca2+oscillations in
cells that do not have any baseline activity (Fig. 7A). Other cells
can display Ca2+oscillations at low ﬂow (Fig. 7B). Increasing ﬂow
can alter the pattern of oscillations (Fig. 7B). Some cells display
rhythmic Ca2+ oscillations at low ﬂow and do not change their
response with increase in ﬂow (Fig. 7C). A variety of responses
occur in response to low or high ﬂow (Fig. 7A–F). Oscillations
depend on extracellular Ca2+ levels (Fig. 7).
Restoring extracellular Ca2+ levels to 2 mM evokes a robust
Ca2+ response (Fig. 7F, G). This is typical of activating store-
operated Ca2+ channels and Ca2+ entry (SOCE) to reﬁll the inter-
nal stores. ATP responses in these cells occur in the absence of
extracellular Ca2+ (0.0Ca2+ + EGTA buffer). Treatment with bac-
terial LPS alters/disrupts Ca2+ signaling, ﬂow-dependent re-
sponses, ATP-induced Ca2+ transients, and SOCE responses in
hEGC (Fig. 8G–L and Fig. 8).
DISCUSSION
A novel and important aspect of our study is identiﬁcation
of a molecular signature of the rhEGC phenotype in cells isolated
and cultured from GI surgical specimens. Several steps in our
isolation/culture protocol insured a yield of puriﬁed hEGC for
nanostring analysis of gene expression. First, isolated ganglia
composed of glia, neurons, and ﬁbroblasts were the starting
materials for growing hEGC cultures. Second, a 2-step puriﬁca-
tion process of hEGC by immune-isolation eliminates nonglial
cells and results in a fairly pure population (98%–99%) of hEGCs
in culture7; neurons do not survive in the culture medium used to
grow hEGCs. Third, cells in puriﬁed hEGC cultures are virtually
immune-positive for the glial marker s100b (99%), and lack stain-
ing for ﬁbroblasts or smooth muscle cells.7,10,11
A custom nanostring panel of 107 genes proved to be
a suitable readout in revealing the molecular identity of the
rhEGC phenotype in response to inﬂammation. Bacterial lipo-
polysaccharide (LPS+IFN-g) induced a “rhEGC phenotype” and
caused an increase in mRNA expression of 58% of the genes,
including 54% of inﬂammatory genes, several transcription fac-
tors, 52% of purine genes, 40% of ion channels, a majority of
vesicular-transport proteins, free radical/antioxidant-genes, tight-
junction proteins, certain postreceptor signaling pathways, and
other proteins. In fact, the bacterial toxin highly discriminates
between genes it targets for transcriptional regulation (i.e., among
receptors, enzymes, channels, glial proteins, or tight junction
extracellular Ca2+ levels. Restoring extracellular Ca2+ levels to 2 mM evokes a robust Ca2+ response. This is typical of activating store-operated Ca2+
channels and Ca2+ entry (SOCE) to reﬁll the internal stores. G, Example of a cell responding with a single Ca2+ transient to increase in ﬂow and ATP
response in 0.0 Ca2+ + EGTA. H, I, High ﬂow responses are altered/disrupted after treatment. H–L, Treatment with bacterial LPS alters/disrupts Ca2+
signaling, ﬂow-dependent responses, ATP-induced Ca2+ transients, and SOCE responses. Treatment alters ﬂow-dependent responses, and typical
responses seen in (A–F) are no longer evident. H and I, Flow-dependent responses are rare and rhythmic responses no longer occur. J–L, Other
examples of abnormal Ca2+ responses characterized by lack of a normal ﬂow-dependent response, small response to 0.0 Ca2+ and lack of sen-
sitivity to ATP activation. Finally, the SOCE response is severely hampered (pooled data is in Fig. 8).
Liñán-Rico et al Inﬂamm Bowel Dis  Volume 22, Number 8, August 2016
1826 | www.ibdjournal.org
Downloaded from https://academic.oup.com/ibdjournal/article-abstract/22/8/1812/4561984
by FACOLTA' DI LETTERE E FILOSOFIA user
on 09 March 2018
proteins in the same functional group). Therefore, a 15-fold
increase occurs in mRNA expression of transient receptor poten-
tial channel TRPA1 whereas TRPV1 is only increased by 1.7-
fold. The enzyme that regulates 5-HT metabolism, TPH2 is up-
regulated 4.8-fold in hEGC, whereas mRNA expression of TPH1
(i.e., expressed in enterochromafﬁn cells) remains the same. The
mRNA expression of the nicotinic channel CHRNA7 increased
by 2.6-fold, whereas the toxin did not inﬂuence expression
of several other channels (i.e., K+ channel KCNE1, N-type Ca2+
channel CACNA1B, nicotinic channel CHRNA4). Also, mRNA
expression of the glial s100B protein but not glial GFAP
is up-regulated by bacterial toxin. The mRNA expression of
one tight-junction protein CLDN1 was highly up-regulated by
;30-fold, whereas several others did not change. Treatment with
LPS+IFN-g had no effect on cell viability, and only a modest
inﬂuence on apoptosis as indicated by a slight increase in mRNA
expression of caspase-3.
In this study, we wanted to test the hypothesis that
inﬂammation would cause signiﬁcant alterations in purinergic
signaling pathways in hEGC. Our data indicates that hEGCs
express a full complement of purinergic receptors and enzymes
needed for physiologic regulation of hEGC functions. Transcripts
exist for all 29 purine genes including ATP-gated P2X channels
(P2X2, P2X3, P2X4, P2X5, and P2X7), metabotropic G-protein
FIGURE 8. Bacterial LPS treatment alters and disrupts Ca2+ signaling and Ca2+ oscillations, mechanical activation of hEGC, ATP-induced Ca2+
responses and SOCE responses. A, After treatment, more cells are responsive to low ﬂow with a Ca2+ response than in the absence of treatment. B,
There is a dramatic reduction in ﬂow-dependent Ca2+ responders. Therefore, treatment disrupts mechanosensitivity in hEGC. C, A reduction in
low/high ﬂow Ca2+ responders also occurs with treatment. D, Flow-dependent Ca2+ oscillations are nearly abolished by treatment. E, After
treatment, cells are no longer sensitive to 10 mM ATP. It does not elicit a Ca2+ transient. F, SOCE Ca2+ responses are severely attenuated by
treatment. Chi-square analysis was used to analyze data, and P values are shown. Numbers of cells responding are shown above the bars.
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coupled P2Y receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12,
P2Y13, and P2Y14), adenosine receptors (A1, A2a, A2b, and A3), as
well as enzymes involved in the metabolism of endogenous nu-
cleotides, nucleosides, and di-nucleotides. These enzymes include
adenosine monophosphate (AMP)/ADA enzymes (AMPD3,
AMPD2, ADA1, and ADA2), ectonucleoside triphosphate di-
phosphohydrolases (ENTPD1, CD39; ENTPD2, and ENTPD3),
nicotinamide enzymes (NADSYN1, NMRK1, and NMNAT1),
NT5E (CD73), and DDP4. The highest constitutive expression
of mRNA for purine genes is for DDP4, CD73, AMPD3,
NMRK1, NMNAT1, P2RX5, and P2RY11; in the inﬂamed state,
mRNA expression of only AMPD3 was increased, and hence the
other 6 highly expressed purine genes are not regulated by
inﬂammation.
LPS induction caused selective up-regulation in mRNA
expression of subsets of receptors and enzymes in hEGC.
Therefore, 9/17 (53%) receptors and 6/13 (46%) enzymes were
regulated by inﬂammation. The order of highest to lowest up-
regulation was Adora2a (27-fold) . AMPD3 (8.3-fold) .
P2RY13 (6-fold) . P2RY2 (4.3-fold) . P2RX3, P2RX7
(4-fold) . P2RY1, P2RY14, P2RY6, ENTPD2, ENTPD3
(3-fold) . NADSYN1 (2-fold) . Adora2b (1.7-fold). From pre-
vious studies, purinergic signaling pathways are known to be
sensitive to inﬂammation and changes in purinergic gene
expression occurs for receptors and enzymes in purinergic path-
ways in response to gut inﬂammation.14–17 This study revealed for
the ﬁrst time that purine gene dysregulation is an important mech-
anism in the rhEGC phenotype.
Our data support the novel hypothesis that bacterial toxin
(or inﬂammation) induces a phenotypic switch from ATP
signaling to other forms of purinergic signaling. The supporting
arguments are brieﬂy discussed. First of all, AMPD3 (and
ENTPD3 to a lesser extend) is up-regulated favoring the
breakdown of ATP. Secondly, the PDE4B/cAMP/CD73 adeno-
sinergic pathway is facilitated by bacterial toxin. For instance,
PDE4B, the enzyme for breaking down cAMP to AMP is up-
regulated, whereas protein kinase A, the target enzyme for cAMP
is down-regulated. This favors a pathway towards AMP and
adenosine production. In fact, as noted, the mRNA expression of
CD73 (NT5E) is not altered by inﬂammation but this enzyme has
the highest constitutive expression of mRNA among 29 purine
genes analyzed. This is signiﬁcant because CD73 is a membrane-
bound enzyme in the PDE4B/cAMP/CD73 adenosinergic path-
way that converts AMP produced from cAMP, release from the
cells to adenosine. Adenosine activates A2a and to a lesser extent
A2b receptors. A2a expression is up-regulated by 27-fold in
response to bacterial toxin, A2bR is modestly up-regulated and
A1/A3 are not affected. ADA (2 isoforms, ADA1/ADA2) that
inactivates adenosine or DDP4 that inhibits ADA is not affected
by treatment. The mRNA counts for both CD73 and DPP4 are
very high in hEGC compared with other purine genes. Therefore,
conservation of expression of these genes would insure that ad-
enosinergic signaling is spared by LPS induction. There is also
a 8.3-fold up regulation of mRNA levels of AMPD3. AMPD3
converts ATP to ADP to AMP and adenosine. Speciﬁcally, data
are consistent with facilitation of the cAMP (PDE4/PKACA)-
dependent adenosinergic A2A pathway and relevant pathway en-
zymes (AMPD3/ENTPD2/DDP4/ADA1 and ADA2). Finally,
ATP-dependent functional signaling is disrupted in hEGC by
treatment. The stimulatory effect of exogenous ATP on Ca2+
responses in hEGC is mitigated by bacterial toxin treatment, even
in the presence of higher basal release of ATP in response to
treatment.
The mRNA expression of CD39 (ENTPD1), an ectonucleo-
side triphosphate diphosphohydrolase is not altered in hEGC.
ENTPD2 and ENTPD3 are up-regulated by LPS+IFN-g in hEGC.
Up-regulation of P2Y1 and P2Y13 receptors favors ADP signaling
in hEGC, whereas the up-regulation of P2Y2 and P2Y6 receptors
favors UTP signaling. Taken together, our data support the novel
hypothesis that bacterial LPS induces a phenotypic switch from
nucleotide/ATP to ADP signaling (P2Y1/P2Y13), adenosinergic
signaling (A2a/A2b), and UTP signaling (P2Y2/P2Y6) in the
rhEGC phenotype that will likely disrupt glial physiology,
because purines are important regulators of Ca2+ signaling in
hEGCs.11,18 Mechanistic studies can test this hypothesis.
The ectoenzymes ectonucleoside triphosphate diphospho-
hydrolase (CD39) and ecto-50nucleotidase (CD73) regulate break-
down of ATP and ADP to AMP and conversion of AMP to
TABLE 2. Signiﬁcant Interactions Between Purine
Genes and Inﬂammatory Genes
Purine Gene
Inﬂammatory Genes
Increase in Slope “m”a Decrease in Slope “m”b
Adora2a IL-6,c IL-8, GATA_3,
CLDN1
C3
AMPD3 SOCS3c CCL2,c IP10, IL-4, IL-8
NT5E/CD73 STAT3,c GATA3 C3, IL-33
ENTPD2 IL-6, IL-8, GATA3,
CLDN1, CCL3
C3
ENTPD3 GATA_3, IP10 GMCSF
P2XR3 C3
P2RX7 CCL2, IL-12_A, IL-17A,
IL-4, IL-6, IL-8, IP10
P2RY6 CCL2, GATA_3, IL-17A,
IL-4, IL-8, IP10
P2RY1 C3, IL-4
Related gene
Panx1 CASP3, P2XR5
aSigniﬁcant increase in the slope of the linear relationship plotted between the
inﬂammatory gene (X1) versus the purine gene (Y1) (P , 0.01 denotes signiﬁcant differ-
ences in slope “m” of line Y1 ¼ m1X1 + B1).
bSigniﬁcant decrease in the slope of the linear relationship plotted between the
inﬂammatory gene (X2) versus the purine gene (Y2) (P , 0.01 denotes signiﬁcant differ-
ences in slope “m” of line Y2 ¼ m2X2 + B2).
cSigniﬁcant interactions.
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adenosine, respectively. This adenosine mechanism is important
in protecting against development of inﬂammation.19–21 Both A2a
and A2b could be involved in protection. Methotrexate and sulfa-
salazine are drugs used to treat IBD, and their mechanism of
action is in part via enhanced release of extracellular adenosine
via a CD73-dependent mechanism.21,22 Dipyridamole is a nucleo-
side uptake inhibitor, and by elevating extracellular levels of
adenosine, it is effective in suppressing the inﬂammatory response
in experimental human endotoxemia. In Chagas disease (i.e.,
infection with Trypanosoma cruzi), CD39 is reduced in lympho-
cytes of patients with the disease.23
In human colon, glia outnumber neurons 7 to 1,24,25 sug-
gesting a more prominent role of glia in human than rodent ENS,
where up-regulation of ectonucleotidases can be a critical neuro-
protective mechanism, to limit neuronal cell death through release
of large amounts of ATP from cell lysis acting on the cytotoxic
P2X7/Panx1 receptor pathway in neurons. Glial cells play a similar
role with glutamate,26 and uptake of glutamate by glia prevents
high extracellular levels that could potentially be neurotoxic.
In astrocytes, LPS was shown to enhance ATP hydrolyzing
activity by different mechanisms. IFN-g decreases the relative
abundance of NTPDase227 and changes the nucleotide phospho-
diesterase (NTPDase) ratio towards NTPDase1, which contributes
to formation of adenosine (to act on P1 receptors). In contrast LPS
up-regulates NTPDase2 and contributes to accumulation of ADP
and activation of P2Y receptors. NTPDase2 converts ATP to ADP
(P2Y1, P2Y12, and P2Y13), and NTPDase1 bypasses the forma-
tion of ADP and forms adenosine (P1).28 We did not test LPS and
IFN-g separately in hEGC to evaluate stimulus-speciﬁc modula-
tion of NTPDases expression. In rodent colon, neurons express
NTPDase 3 and enteric glial cells express NTPDase2.29
NTPDase2 is the dominant ectonucleotidase expressed in rat as-
trocytes as well.27 We found mRNA expression of all 3 ecto-
50nucleotidases in hEGC, and the expression of NTPDase 2 and
3 is modulated by inﬂammation. High NTPDase 2 and NTPDase
3 activity in the LPS-induced rhEGC phenotype may provide
a protective mechanism for glia and neurons from high levels of
extracellular ATP that can cause neurotoxicity and neuronal cell
death, as shown for IBD30 or in vitro model of ischemia,31 cell
cultures, or organotypic culture.32 A shift to ADP/adenosine is
presumed to be neuroprotective by suppressing neuronal excit-
ability through inhibitory A1/A3 sites in human ENS. In the cen-
tral nervous system, astrocytes are the main source of extracellular
nucleotides, and important regulatory enzymes exist for control
of external concentration of nucleotides. Ectonucleotidases
constitute a complex enzymatic cascade to regulate nucleotide
signaling, controlling rate, amount and timing of nucleotide
degradation, and nucleoside/adenosine formation. Alterations in
expression of these enzymes may disrupt hEGC physiology.
Metabotropic P2Y receptors that are up-regulated are P2Y1,
P2Y2, P2Y6, P2Y13, and P2Y14. The endogenous ligands for these
receptors are ADP for P2Y1 and P2Y13, UTP for P2Y2 and P2Y6,
and uridine diphosphate-glucose for P2Y14.
13 Among nucleotides,
our previous study showed that UTP activates more hEGCs than
ATP or other agonists,10,11 and therefore UTP responses in addi-
tion to adenosine responses may play a more prominent role in the
rhEGC phenotype. In other studies in the past, inﬂammation was
shown to alter enteric glial cell expression of mGluR533 and en-
dothelin receptors in animals.34 These possibilities will be
explored in future studies.
The P2Y13 receptor is involved in apoptosis of neurons in
the ENS, and neurons of the ENS in P2Y13 receptor null mice are
resistant against high fat diet and palmitic acid–induced neuronal
loss.35 Our study identiﬁed for the ﬁrst time mRNA expression of
P2Y13 in hEGC, and expression is ;6-fold up-regulated by bac-
terial LPSs. The P2Y13 receptor is a target of interest in GI
inﬂammatory disorders for apoptosis/neuroprotection. Overall,
A2a, AMPD3, P2Y13, P2Y2, P2X3, and P2X7 are novel purinergic
targets in the rhEGC phenotype, and their level of up-regulation
(4–27-fold) is expected to cause abnormal purinergic Ca2+ signal-
ing, Ca2+ waves, and glial modulation of neural and motor
behavior.12
Preliminary data show that basal secretion of ATP, ADP,
AMP, ADO, and NAD occurs in hEGC,10 and enzymes exist for
degradation of the endogenous ligands. Remarkably, basal release
of ATP was increased 5-fold by LPS induction, whereas s100B
release was reduced by induction in hEGC. The mechanism is not
known, but what is known is that inﬂammation, and speciﬁcally
IL-1b and TNF-a can cause opening of hemichannels in glia that
can release large molecules such as ATP, glutamate or others,
which can kill neurons in co-culture through activation of pan-
nexin hemichannels (Panx1). The mRNA levels of these pro-
inﬂammatory cytokines were up-regulated in hEGC in response
to LPS induction, and hemichannels could potentially be
involved. Panx1 is also up-regulated in hEGC, and it may be
important in human glial pathophysiology as in astrocytes.36
Whether other hemichannels are expressed or up-regulated with
inﬂammation is not known in hEGC. But, we now know that
multiple hemichannels may be involved in cell-to-cell communi-
cation in hEGC and may include connexins and pannexins.10
Another possibility is that up-regulation of vesicular transport
proteins facilitates basal ATP release in hEGC. The mRNA
expression of 3 proteins (SYT2, SNAP25, and SYP) was
increased 3.6 to 6-fold by bacterial toxin. SYT2, synaptosomal
associated protein SNAP25 and synaptophysin are up-regulated,
suggesting a role in gliotransmission in inﬂamed states. The func-
tional roles of purinergic signaling pathways in normal and in-
ﬂamed states of hEGC await further investigation.
Our recent preliminary studies showed that hEGC is a useful
model to study glial function.10,11 MS plays a key role in the
physiology of hEGC–they trigger Ca2+ oscillations and Ca2+
waves in hEGC. In this study, we found that there is clear and
discrete change in ﬂow-dependent activation of hEGC that trig-
gers Ca2+ oscillations. After bacterial toxin treatment, hEGC
change their behavior by being less responsive to MS. Treatment
increased sensitivity of cells at low ﬂow and almost prevented
ﬂow-dependent Ca2+ responses. We propose that such a D me-
chanosensitivity will alter the ability of hEGC to respond to MS
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(i.e., muscle contractions, increase in intraluminal pressure, dis-
tension, and stretch or deformation of glial membranes) associated
with various physiologic motor patterns (i.e., peristalsis, propul-
sion, colonic migrating motor complexes, mass movement/evac-
uation reﬂex during defecation, the migrating motor complex
(MMC), or mixing movements during the digestive phase). LPS
further disrupts Ca2+ dynamics, as indicated by a severely dimin-
ished SOCE Ca2+ response. In addition, the Ca2+ response
induced by ATP is severely disrupted as noted earlier. MS is
known to trigger release of purines like ATP in most cells.17,37
We propose that a D mechanosensitivity in hEGC would contribute
to abnormal neuromuscular function and motility by disrupting Ca2+
and purinergic signaling, because MS and ATP trigger both Ca2+
oscillations and Ca2+ waves in glia, events that are linked to
motility.2,12 Another contributing factor is a shift in purinergic sig-
naling from ATP to ADP, UTP, and adenosinergic signaling as
indicated by changes in molecular signaling of purinergic pathways.
The NFkB signaling transcription pathway is an important
pro-inﬂammatory pathway in EGC that contributes to harmful
effects of the reactive glial phenotype. In hEGC, NFkB signaling
is involved in the TLR/RAGE/s100B–dependent iNOS/NO sig-
naling pathway induced by LPS or pathogenic bacteria7 and ulcer-
ative colitis in humans,38 as well as DSS colitis in mice.8,39,40
STAT3 (signal transducer and activator of transcription 3) and
SOCS3 (suppressor of cytokine signaling 3) are involved in neg-
ative regulation of cytokines and their expression in hEGC was
increased in response to LPS. STAT3 is known to suppress pro-
inﬂammatory signaling mechanisms in astrocytes.41 The mRNA
counts/sample for STAT3 was the highest for all transcription
factors (i.e., .1000 mRNA counts versus #50 mRNA counts/
100 ng RNA sample for 6 other transcription factors), and its
expression increased in response to LPS. This suggests an impor-
tant role in the physiology of EGC and in dampening inﬂamma-
tory responses in hEGC. FOXP3 is up-regulated by 4.5-fold.
FOXP3 is a master regulator/transcription factor involved in
immune responses, development and function of regulatory
T cells. Deﬁciency is associated with multi-organ autoimmunity
in Scurfy mutant mice and human patients with enteropathy and
other syndromes.42 Our study extends our knowledge, and pro-
vides evidence that the transcription factors RelB, RelA, SOCS3,
FOXP3, GATA_3, and aryl hydrocarbon receptor are up-
regulated by LPS–. Overall, the net effect of transcriptional reg-
ulation is to induce a detrimental rhEGC phenotype.
Toll-like receptors (TLRs) are receptors that mediate innate
immune responses in astrocytes and EGC. TLRs recognize LPS
(a membrane component of Gram-negative bacteria) such as
Enteroinvasive E. coli. Bacterial LPS activates multiple TLRs in
hEGC,7 and it is likely that not all changes in the rhEGC pheno-
type are the result of a single TLR activation. TLR4 activation
causes NO production through an s100B/RAGE/iNOS mecha-
nism. In this study, the TLR signaling mechanisms linked to gene
dysregulation in the rhEGC is unknown. In astrocytes TLR3 sig-
naling induces the strongest pro-inﬂammatory response involving
secretion of high levels of IL-12, TNF-a, IL-6, CXCL-10 (IP10),
and IL-10.43 CCL2, CCL5, 7, 8, 12 are also activated in astrocytes
in response to LPS.41 In hEGC, TLR4 signaling involves MyD88/
RAGE/s100B-iNOS/NO signaling pathway through NFkB sig-
naling.7 Palmitoylethanolamide exerts its anti-inﬂammatory
effects by targeting the s100B/TLR4 dependent peroxisome
proliferator-activated receptors a activation on EGC, causing
a downstream inhibition of NFkB-dependent colonic inﬂamma-
tion.8 Our study identiﬁed many new signaling pathways linked to
global activation of TLRs in hEGC by LPS. Highly regulated
genes included both chemokines and cytokines, but the response
was overwhelmingly pro-inﬂammatory or detrimental, although
a few anti-inﬂammatory genes were also increased with LPS.
Pro-inﬂammatory chemokine up-regulation of expression from
highest to lowest was in the order of IP10 (CXCL-10) ..
Cxcl2 ¼ CCL3 . CCL2 (MCP-1) . s100B; s100B is proposed
to represent a marker of the severity of inﬂammation in ulcerative
colitis,6,7 and is implicated in TLR signaling in response to LPS or
E. coli infection in hEGC.7 At least in hEGC, much stronger up-
regulation occurs for 4 other chemokines (e.g., s100B increased
by 3-fold versus Cxcl2 of greater than 1000-fold and CCL3
[150-fold], CCL2 [MCP1, 12-fold] and IP10 [CXCL-10, .
10,000-fold], v. low basal levels). Their mechanism of action is
not known. Pro-inﬂammatory cytokine genes that were strongly
up-regulated included from high to low IL-8 . IL-6, IL-1b,
TNF-a, IL-4 . IL-23A, IL-33, IL-17A, IL-12A, and IL-2R.
Among the cytokines, IL-10 and IL-22 are the only anti-
inﬂammatory cytokines.44–46 that displayed up-regulation (5–7-
fold) in hEGC. Expression of transforming growth factor beta 1
did not change with LPS. Neutralizing antibodies have shown the
therapeutic potential of IL-23 and IL-12 in experimental colitis
and clinical trials of IBD, speciﬁcally in patients with CD resistant
to TNF-a therapy.47,48 In hEGC, up-regulation of IL-23A (20-
fold) is much greater than IL-12 (5-fold). It is tempting to spec-
ulate that hEGC is one of the cellular targets for the beneﬁcial
effects of antibody therapy in CD, especially since E. coli bacte-
rial infection is a prominent feature in ;36% of CD patients with
ileal involvement,49 and these responses are likely to occur in
hEGC in these patients. Various cytokines and chemokines
released by reactive hEGC could potentially have a profound
effect on surrounding cells in the gut including other glia in the
networks, immune cells, neurons, interstitial cells of Cajal (ICC),
enteroendocrine cells and epithelial cells.
TLR2 signaling regulates intestinal inﬂammation in a pro-
tective manner by controlling ENS structure neurochemical
coding, as well as neuromuscular function. These data provide
some insight as to how TLR2 signaling in the ENS may affect the
IBD phenotype in humans.50 LPS also enhanced the action of
bradykinin in the ENS by secretion of IL-1b from rat EGCs.51
LPS/cytokines stimulate release of NO, IL-1b, IL-6, and PGE2
from rodent EGC.52 The current study in hEGC identiﬁed the
nature of the pro-inﬂammatory response to LPS that can directly
contribute to intestinal inﬂammation. IL-1b expression was up-
regulated 25-fold in hEGC. IL-1b signaling in EGC was shown to
be involved in POI in the mouse.9 IL-1b also attenuates EGC
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proliferation whereas LPS and IFN-g together stimulate glial cell
proliferation.37 We identiﬁed a large number of pro-inﬂammatory
genes that are regulated by LPS induction.
Inﬂammatory cytokines modify intracellular free Ca2+ levels
in EGC and regulate expression of glial proteins GFAP and s100B,
and these responses are pro-inﬂammatory and detrimental.7,9,51 In
our study of hEGC, LPS increased s100B but not GFAP mRNA
expression. In vivo intestinal inﬂammation stimulates proliferation
of myenteric EGC.53 NO contributes to pro-inﬂammatory reactions.
TH1 associated cytokines are IFN-g and IL-2, and in the
presence of LPS, their expression levels were increased by 5 to
6-fold. TH2-type cytokines include IL-5, IL-4, and IL-13 associated
with transcription factor GATA3.54 Only IL-4 expression increased
by LPS, but the increase was 20-fold. Therefore, Th1 and Th2
associated cytokine genes are altered in different ways in hEGC.
EGC may exert a neuroprotective role for enteric neurons
from oxidative stress–induced cell death and increase neuronal
survival in part by reduced glutathione.55 The glial mediators glu-
tathione, glial cell line-derived neurotophic factor (GDNF) and
15dPGJ2 exert neuroprotective effects.55,56 In astrocytes, up-
regulation of SOD2 and catalase attenuates oxidative stress.57
Astrocyte depletion impairs redox homeostasis and triggers neuro-
nal loss in the adult central nervous system; neutralization of reac-
tive oxygen species and reactive nitrogen species protects against
neural injury.58 Earlier reports suggested that neurons depend on
antioxidant potential of astrocytes for their own defense against
oxidative stress in vitro.59 There is critical involvement of astro-
cytes in redox homeostasis and lesioning of astrocytes in vivo leads
to oxidative stress and neuronal decline. From a translational view-
point, neuroprotective interventions might be more likely to suc-
ceed if they target metabolic integrity of the glia-neuron interface. It
is highly signiﬁcant therefore, that in hEGC, mRNA expression of
SOD2 is up-regulated by 45-fold in response to LPS. It inactivates
highly reactive superoxide free radicals and converts O2- to hydro-
gen peroxide. It is a signal that free radicals are elevated in the
rhEGC. This is a novel protective mechanism that may provide
glial and neuronal protection in an effort to preserve the normal
neural-glial environment in human ENS. Free radicals increase the
permeability of Cx43 hemichannels to large molecules or their
open probability60 and they are involved in Ca2+ waves in hEGC.10
A novel ﬁnding is that HMOX1 mRNA level is increased by
2-fold in hEGC in response to LPS. The heme-degrading enzyme
HMOX1 promotes iron deposition, mitochondrial damage, and
autophagy in astrocytes and enhances vulnerability of neurons to
oxidative stress/injury. It is suggested that in chronic central
nervous system disorders, over-expression of glial HMOX1 may
contribute to neural damage.61 This may have implications for GI
disorders with ENS dysfunction. The inducible NO synthase
enzyme (NOS2) is also up-regulated in hEGC by 6-fold. Increase
in NO production has been shown to involve a TLR/RAGE/s100B–
iNOS/NO pathway in hEGC.7 Increased production of NOS2 in
enteric glia contributes to dysregulation of intestinal ion transport in
mice with colitis. Blocking EGC function restores epithelial barrier
function and also decreases bacterial translocation.39
Data analysis suggested that signiﬁcant interactions exist
between purine genes and inﬂammatory genes (i.e., a change is
slope of the linear relationship between mRNA expression of
speciﬁc purine genes and inﬂammatory genes). A positive or
negative interaction is revealed between purines and inﬂammatory
genes depending on the speciﬁc purine gene. This supports the
hypothesis that expression of speciﬁc purine genes is regulated by
different mechanisms. It is likely that complex interactions exist
between inﬂammation and purinergic signaling pathways and that
speciﬁc inﬂammatory mediators generated by LPS-induction of
hEGC (or gut bacterial infection) differentially modulate purine
gene expression. This provides a short list of purine genes (9 of 29)
and candidate inﬂammatory targets for testing it in future studies.
A working model of the molecular signaling pathways
activated in the rhEGC phenotype is illustrated in Figure 9. Our
ﬁndings provide signiﬁcant new insights into the molecular mech-
anisms and pathophysiology of the rhEGC phenotype. Discrete
up-regulation of mRNA expression levels occurred in certain
genes. Major molecular pathways of dysregulation include
inﬂammatory mediators, growth factors, transcription factors,
purine genes, vesicular transport proteins, free radical pathways,
angiotensin receptors, TRP channels, Panx1 hemichannels, en-
zymes for metabolism of 5-HT, purine nucleosides, nucleotides
and di-nucleotides, a barrier protein CLDN1 and cAMP-
dependent pathways PDE4/PKACA. As shown in Fig. 9A, our
working hypothesis is that LPS induction (or bacterial infection)
activates TLRs leading to transcriptional regulation (via SOCS3/
STAT3/GATA_3/RELA/RELB) and up-regulation of inﬂamma-
tory genes (including cytokines, chemokines and growth factors).
Inﬂammatory mediators and transcription factors work in concert
to cause dysregulation/up-regulation in gene expression proﬁles
of selected clusters of purine genes, TRP channels, neurotrans-
mitters/signaling, vesicular transport proteins, second messengers,
junction/barrier proteins, and free radical pathways. The receptors
and molecular signaling pathways affected by bacterial LPS are
illustrated in Fig. 9B. Bacterial LPS induction disrupted glial
function and altered mechanosensitivity, ATP Ca2+ responses,
ATP (and s100B) release, and Ca2+ handling mechanisms (i.e.,
SOCE response). Changes in these molecular signaling pathways
in response to inﬂammation would disrupt motility and intestinal
transit. Overall, speciﬁc changes in the rhEGC phenotype include
(1) DCa2+ signaling, (2) D purinergic signaling, (3) DPanx1 hemi-
channels, (4) switch from ATP to ADO/ADP/UTP signaling, (5)
D vesicular transport proteins that may facilitate release of ATP,
(6) D transmitter signaling, (7) D Sensory signaling, (8) D free
radical/antioxidant pathways, (9) D Ca2+ waves10,11 and (10) a D
in receptor expression.
This study identiﬁed a large piece of the puzzle related to
the rhEGC phenotype activated by bacterial toxin. The ENS is
affected in patients with neurological and GI disorders (slow
transit constipation, irritable bowel syndrome, motility, Chagastic
megacolon). Some of the highly regulated genes in hEGC may
have implications for IBD, and in particular CD for which data
suggest that bacteria play a role in the onset and propagation of
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IBD. Invasive E. coli is restricted to CD, and is isolated from ileal
biopsies of 36% of CD patients with ileal involvement. The path-
ogenesis of CD is postulated to be closely linked to the presence
of invasive E. coli. In IBD, dysbiosis may induce a breakdown in
the balance between “putative species of harmful (i.e., adherent-
invasive E. coli) and protective bacteria” (Biﬁdobacterium &
Lactobacillus species) (48). The inﬂuence of other products (e.
g., ﬂagellin) and invasive bacteria such as Shigella ﬂexneri, enter-
otoxinogenic E. coli, Listeria monocytogenes, and Yersinia enter-
ocolitica on hEGC remains unknown.
The molecular phenotype represents many novel potential
therapeutic targets of investigation in hEGC for treating motility
FIGURE 9. A working hypothesis of the molecular signaling pathways activated in the rhEGC phenotype in response to bacterial LPS activation.
Gene expression was altered in 58% of genes (107 genes) including 54% of inﬂammatory genes, 52% of purine genes (15 of 29 genes), 40% of
channels, vesicular transport proteins, transcription factors, free radical pathways, second messenger systems, and other proteins. Ninety-ﬁve
percent of genes were up-regulated by treatment. A, Our working hypothesis is that LPS induction (or bacterial infection) activates TLRs leading to
transcriptional regulation (via SOCS3/STAT3/GATA_3/RELA/RELB) and up-regulation of inﬂammatory genes (including cytokines, chemokines and
growth factors). Inﬂammatory mediators and transcription factors work in concert to cause dysregulation/up-regulation in gene expression
proﬁles of selected clusters of purine genes, TRP channels, neurotransmitters/signaling, vesicular transport proteins, second messengers, junction/
barrier proteins, and free radical pathways. The receptors and molecular signaling pathways are affected by bacterial LPS (B). Overall disruption in
glial molecular signaling pathways is likely to contribute to abnormal Ca2+ waves, gliotransmission, purinergic signaling, and mechanosensitivity.
Propulsion and ﬂow of contents in the lumen of the intestinal tract occurs as a result of oral CM contraction in the propulsive/oral segment and
distal relaxation in the receiving segment to allow ﬂow/movement of luminal contents. Mechanical forces generated during peristalsis (D in-
traluminal pressure, compression forces, tactile stimulation, D ﬂow, CM contraction, or the peristaltic wave) can trigger Ca2+ waves in hEGC to
modulate ENS activity and motor behavior. Purinergic signaling also triggers Ca2+ waves in hEGC. Changes in these molecular signaling pathways
in response to inﬂammation would disrupt motility and intestinal transit. Speciﬁc changes in the rhEGC phenotype include (1) D Ca2+ signaling, (2)
D purinergic signaling, (3) DPanx1 hemichannels, (4) switch from ATP to Ado/ADP/UTP signaling, (5) D vesicular transport proteins that may
facilitate release of ATP, (6) D transmitter signaling, (7) D sensory signaling, (8) D free radical/antioxidant pathway, (9) D Ca2+ waves, and (10) a D in
receptor expression. A rhEGC and those genes and pathways represent new targets of investigation in diseases involving infection, intestinal
inﬂammation, neurologic disorders, and GI disorders.
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disorders (and slow transit constipation),12 GI disorders,1 IBD,62
POI,9 and infectious diseases.7 Both animal studies2,3 and human
in vitro studies strongly support the concept that EGCs are
involved in the modulation of motor function in the intestinal
tract.12 Inﬂammation may change the overall pattern of purinergic
signaling by causing up-regulation in 9 receptor genes (A2a,
P2Y13, P2Y2, P2X3, P2X7, P2Y1, P2Y14, P2Y6, and A2b) and 6
purinergic enzymes (AMPD3, ENTPD3, ENTPD2, NADSYN1,
etc). Our study tested a single inﬂammatory stimulus, but the
molecular phenotype may depend on the type of stress or injury,63
and the type of inﬂammatory stimulus, severity or chronicity of
inﬂammation is also likely to have an impact on the molecular
phenotype. Reactive hEGC induced by LPS exhibited a pro-
inﬂammatory phenotype that was overwhelmingly detrimental,
although several protective genes were up-regulated (i.e., IL-10,
IL-22, SOD2, SOCS3, STAT3, Wnt-b-catenin signaling, and ad-
enosinergic pathways). The importance of studies in EGC is high-
lighted by the fact that EGCs represent a transcriptionally unique
population of glia in the mammalian nervous system.65
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